Cargando…

Sarcopenia and myosteatosis diagnostic tool for gastrointestinal cancer: creatinine to cystatin C ratio as evaluation marker

OBJECTIVE: This study aimed to develop a simplified diagnostic tool for assessing sarcopenia and myosteatosis in gastrointestinal cancer patients, focusing on the creatinine to cystatin C ratio (CCR) as an evaluation marker. METHODS: 955 patients were split into training (n = 671) and validation (n ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hao, Wang, Junjie, Tan, Shanjun, Zhang, Zhige, Yan, Mingyue, Han, Jun, Sui, Xiangyu, Yang, Fan, Wu, Guohao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589997/ https://www.ncbi.nlm.nih.gov/pubmed/37864250 http://dx.doi.org/10.1186/s12967-023-04628-z

Ejemplares similares

Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours
por: Ding, Ping’an, et al.
Publicado: (2022)

Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer
por: Sun, Jing, et al.
Publicado: (2022)

Serum creatinine/cystatin C ratio is a surrogate marker for sarcopenia in patients with idiopathic pulmonary fibrosis
por: Fujita, Kohei, et al.
Publicado: (2022)

Serum creatinine/cystatin C ratio as a screening tool for sarcopenia and prognostic indicator for patients with esophageal cancer
por: Zheng, Chao, et al.
Publicado: (2022)

Creatinine-to-cystatin C ratio as a marker of sarcopenia for identifying osteoporosis in male patients with type 2 diabetes mellitus
por: Dai, Huifan, et al.
Publicado: (2022)

Correction: Creatinine‑to‑cystatin C ratio as a marker of sarcopenia for identifying osteoporosis in male patients with type 2 diabetes mellitus
por: Dai, Huifang, et al.
Publicado: (2022)

Serum cystatin C to creatinine ratio is associated with sarcopenia in non-dialysis-dependent chronic kidney disease
por: An, Jung Nam, et al.
Publicado: (2022)

Diagnostic Value of Serum Creatinine and Cystatin-C-Based Indices and Ishii Score in Cancer-Related Sarcopenia
por: Ding, Liming, et al.
Publicado: (2023)

Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment
por: Jördens, Markus S., et al.
Publicado: (2021)

MON-LB073 The Serum Creatinine to Serum Cystatin C Ratio Is a Reliable Surrogate Marker of Sarcopenia in Patients with Cushing's Syndrome in Remission
por: Martel, Luciana, et al.
Publicado: (2019)

High prevalence of sarcopenia and myosteatosis in patients undergoing hemodialysis
por: Fu, Chen, et al.
Publicado: (2023)

Serum creatinine and cystatin C‐based diagnostic indices for sarcopenia in advanced non‐small cell lung cancer
por: Tang, Tianjiao, et al.
Publicado: (2022)

Sarcopenia and Myosteatosis Are Associated with Neutrophil to Lymphocyte Ratio but Not Glasgow Prognostic Score in Colorectal Cancer Patients
por: Aro, Raila, et al.
Publicado: (2022)

A Novel Application of Serum Creatinine and Cystatin C to Predict Sarcopenia in Advanced CKD
por: Lin, Yu-Li, et al.
Publicado: (2022)

Mitophagy-mediated inflammation and oxidative stress contribute to muscle wasting in cancer cachexia
por: Zhang, Zhige, et al.
Publicado: (2023)

Psoriasis Is Associated With Myosteatosis but Not Sarcopenia: A Case-Control Study
por: Chen, Xiaomei, et al.
Publicado: (2021)

Effects of sarcopenia and myosteatosis are alleviated in reduced port surgery for diverticulitis
por: Schaffler-Schaden, Dagmar, et al.
Publicado: (2023)

Sarcopenia Index Based on Serum Creatinine and Cystatin C is Associated with Mortality, Nutritional Risk/Malnutrition and Sarcopenia in Older Patients
por: Ren, Chenxi, et al.
Publicado: (2022)

The impact of sarcopenia and myosteatosis on postoperative outcomes in patients with inflammatory bowel disease
por: O’Brien, Stephen, et al.
Publicado: (2018)

Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound
por: Lortie, Jevin, et al.
Publicado: (2022)

Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Kim, Dong Wook, et al.
Publicado: (2022)

Clinical significance of serum cystatin C‐to‐creatinine ratio as a surrogate marker for incident osteoporotic fracture predictions
por: Yoshii, Ichiro, et al.
Publicado: (2023)

Usefulness of serum creatinine and cystatin C ratio as a screening tool for predicting prognosis in patients with pancreatic cancer
por: Tsukagoshi, Mariko, et al.
Publicado: (2023)

Diagnostic and prognostic value of the Creatinine/Cystatin C ratio for low muscle mass evaluation among US adults
por: Shi, Shanshan, et al.
Publicado: (2022)

Diagnostic evaluation of urea nitrogen/creatinine ratio in dogs with gastrointestinal bleeding
por: Stiller, Jenny, et al.
Publicado: (2021)

Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas
por: Stretch, Cynthia, et al.
Publicado: (2018)

Sarcopenia and Myosteatosis at Presentation Adversely Affect Survival After Esophagectomy for Esophageal Cancer
por: Srpcic, Matevz, et al.
Publicado: (2020)

Corrigendum: Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound
por: Lortie, Jevin, et al.
Publicado: (2022)

The effect of computed tomography parameters on sarcopenia and myosteatosis assessment: a scoping review
por: Lortie, Jevin, et al.
Publicado: (2022)

Sarcopenia index based on serum creatinine and cystatin C is associated with 3-year mortality in hospitalized older patients
por: Tang, Tianjiao, et al.
Publicado: (2020)

Utility of serum creatinine/cystatin C ratio in diagnosis of postrenal acute kidney injury
por: İnal, Salih, et al.
Publicado: (2014)

Creatinine–cystatin C ratio and mortality in cancer patients: a retrospective cohort study
por: Jung, Chan‐Young, et al.
Publicado: (2022)

Serum creatinine/cystatin C ratio as a prognostic indicator for patients with colorectal cancer
por: Gao, Shunhui, et al.
Publicado: (2023)

Diagnosing sarcopenia and myosteatosis based on chest computed tomography images in healthy Chinese adults
por: Tan, Lingling, et al.
Publicado: (2021)

Relationships between cystatin C- and creatinine-based eGFR in Japanese rural community- dwelling older adults with sarcopenia
por: Kusunoki, Hiroshi, et al.
Publicado: (2020)

Serum Creatinine-to-Cystatin C Ratio in the Progression Monitoring of Non-alcoholic Fatty Liver Disease
por: Li, Shaobo, et al.
Publicado: (2021)

Serum creatinine/cystatin C ratio as a case-finding tool for low handgrip strength in Chinese middle-aged and older adults
por: Tan, Lingling, et al.
Publicado: (2020)

Serum creatinine/cystatin C ratio as a muscle mass evaluating tool and prognostic indicator for hospitalized patients: A meta-analysis
por: Zheng, Wen-He, et al.
Publicado: (2023)

Relationship between sarcopenia/myosteatosis and frailty in hospitalized patients with cirrhosis: a sex-stratified analysis
por: Feng, Hongjuan, et al.
Publicado: (2021)

Defining sarcopenia and myosteatosis: the necessity for consensus on a technical standard and standardized cut‐off values
por: Westenberg, Lisa B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hnhs54if3cpptidf6sd34mng4k